Rapport Therapeutics Common Stock Statistics
Share Statistics
Rapport Therapeutics Common Stock has 36.58M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 36.58M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 31.92K |
| FTD / Avg. Volume | 28.47% |
Short Selling Information
The latest short interest is 1.81M, so 4.94% of the outstanding shares have been sold short.
| Short Interest | 1.81M |
| Short % of Shares Out | 4.94% |
| Short % of Float | 10.35% |
| Short Ratio (days to cover) | 14.7 |
Valuation Ratios
The PE ratio is -98.27 and the forward PE ratio is -7.37.
| PE Ratio | -98.27 |
| Forward PE | -7.37 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 24.25 |
| P/FCF Ratio | -118.63 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Rapport Therapeutics Inc. Common Stock.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.14, with a Debt / Equity ratio of 0.02.
| Current Ratio | 17.14 |
| Quick Ratio | 17.14 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.5 |
| Cash Flow / Debt | -12.67 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.25% and return on capital (ROIC) is -25.29%.
| Return on Equity (ROE) | -0.25% |
| Return on Assets (ROA) | -0.22% |
| Return on Capital (ROIC) | -25.29% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -599.76K |
| Employee Count | 58 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 10.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0, so Rapport Therapeutics Common Stock's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 20.67 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 24.58 |
| Average Volume (20 Days) | 112.12K |
Income Statement
| Revenue | n/a |
| Gross Profit | -112.00K |
| Operating Income | -36.18M |
| Net Income | -34.79M |
| EBITDA | -34.66M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.21 |
Balance Sheet
The company has 70.17M in cash and 2.15M in debt, giving a net cash position of 68.02M.
| Cash & Cash Equivalents | 70.17M |
| Total Debt | 2.15M |
| Net Cash | 68.02M |
| Retained Earnings | -45.44M |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was -27.18M and capital expenditures -1.64M, giving a free cash flow of -28.82M.
| Operating Cash Flow | -27.18M |
| Capital Expenditures | -1.64M |
| Free Cash Flow | -28.82M |
| FCF Per Share | -0.18 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RAPP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.66% |
| FCF Yield | -6.23% |
Analyst Forecast
The average price target for RAPP is $35, which is 176.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $35 |
| Price Target Difference | 176.7% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |